Literature DB >> 2772792

Surgical staging of carcinoma of the ovaries.

H J Buchsbaum1, M F Brady, G Delgado, A Miller, W J Hoskins, A Manetta, G Sutton.   

Abstract

One hundred and eighty-seven patients with stages I, II and III optimal (metastatic lesions of less than 3 centimeters) epithelial carcinoma of the ovaries were evaluated preoperatively and had standardized exploration and biopsy. The protocol called for examination and biopsy of the peritoneum, diaphragm, omentum, pelvic and para-aortic lymph nodes and aspiration of ascites or peritoneal washings for cytologic examination. Of those patients with metastases to the omentum, the clinical impression did not correlate with pathologic findings in 45 per cent. The findings were similar for diaphragmatic lymph nodes (50 per cent), pelvic lymph nodes (71 per cent) and para-aortic lymph nodes (96 per cent). Nine of 97 patients clinically thought to have stage I disease had the stage elevated to II and III based on pathologic findings. Similarly, 15 patients thought to have stage II were found to have stage III based on histopathologic findings. There were 74 complications in 54 patients, with 29 having at least one complication. Surgical exploration for early stage carcinoma of the ovary should include biopsy of the retroperitoneal pelvic and para-aortic lymph nodes, excision of the infracolic omentum, biopsies of pelvic and abdominal peritoneum, including the right diaphragm, and peritoneal cytologic studies.

Entities:  

Mesh:

Year:  1989        PMID: 2772792

Source DB:  PubMed          Journal:  Surg Gynecol Obstet        ISSN: 0039-6087


  8 in total

1.  Should we modify the current FIGO staging system for stage IIIC ovarian cancer?

Authors:  Hee-Sug Ryu
Journal:  J Gynecol Oncol       Date:  2008-12-29       Impact factor: 4.401

2.  S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013.

Authors:  U Wagner; P Harter; F Hilpert; S Mahner; A Reuß; A du Bois; E Petru; W Meier; P Ortner; K König; K Lindel; D Grab; P Piso; O Ortmann; I Runnebaum; J Pfisterer; D Lüftner; N Frickhofen; F Grünwald; B O Maier; J Diebold; S Hauptmann; F Kommoss; G Emons; B Radeleff; M Gebhardt; N Arnold; G Calaminus; I Weisse; J Weis; J Sehouli; D Fink; A Burges; A Hasenburg; C Eggert
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-09       Impact factor: 2.915

Review 3.  Pursuit of optimum outcomes in ovarian cancer: methodological approaches to therapy.

Authors:  D D Gibbs; M E Gore
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 4.  Progress in gynecologic cancer research: the Gynecologic Oncology Group experience.

Authors:  George A Omura
Journal:  Semin Oncol       Date:  2008-10       Impact factor: 4.929

5.  POU6F1 is the transcription factor that might be involved in cell proliferation of clear cell adenocarcinoma of the ovary.

Authors:  Norihito Yoshioka; Nao Suzuki; Atsushi Uekawa; Kazushige Kiguchi; Bunpei Ishizuka
Journal:  Hum Cell       Date:  2009-11       Impact factor: 4.174

Review 6.  Early ovarian cancer.

Authors:  G Coukos; S C Rubin
Journal:  Curr Treat Options Oncol       Date:  2000-06

7.  Surgical staging of apparent early-stage ovarian mucinous carcinoma.

Authors:  Zhen Yuan; Ying Zhang; Dongyan Cao; Keng Shen
Journal:  World J Surg Oncol       Date:  2022-09-24       Impact factor: 3.253

8.  Photodynamic diagnosis of ovarian cancer using hexaminolaevulinate: a preclinical study.

Authors:  F Lüdicke; T Gabrecht; N Lange; G Wagnières; H Van Den Bergh; L Berclaz; A L Major
Journal:  Br J Cancer       Date:  2003-06-02       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.